Matthew A. Cooper
Fondatore presso Inflazome Ltd.
Profilo
Matthew A.
Cooper was the founder of Akubio Ltd.
(founded in 2001) and Inflazome Ltd.
(founded in 2016), where he held the titles of Chief Scientific Officer and Chief Executive Officer & Director, respectively.
He is currently a Venture Partner at Forbion Capital Partners Management Holding BV (since 2022).
He previously worked as a Principal at the University of Cambridge.
Dr. Cooper earned a doctorate degree from the University of Adelaide.
Posizioni attive di Matthew A. Cooper
| Società | Posizione | Inizio |
|---|---|---|
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Fondatore | 01/01/2016 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investitore di Private Equity | 20/07/2022 |
Precedenti posizioni note di Matthew A. Cooper
| Società | Posizione | Fine |
|---|---|---|
Akubio Ltd.
 Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Fondatore | 31/05/2010 |
| University of Cambridge | Corporate Officer/Principal | - |
Formazione di Matthew A. Cooper
| University of Adelaide | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Akubio Ltd.
Akubio Ltd. Electronic Equipment/InstrumentsElectronic Technology Akubio Ltd. develops acoustic biosensor instruments. Its products are used in protein research and drug development. The company's technology based on quartz resonators delivers molecular identification and measurement of interactions in complex samples. Akubio was founded by Matthew A. Cooper in August 2001 and is headquartered in Cambridge, UK | Electronic Technology |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
- Borsa valori
- Insiders
- Matthew A. Cooper
